Navigation Links
POZEN Announces Positive Outcome for PA 325 Proof of Concept Study

Food and Drug Administration, and with AstraZeneca for proprietary fixed dose combinations of naproxen with the proton pump inhibitor esomeprazole magnesium in a single tablet for conditions such as osteoarthritis and rheumatoid arthritis in patients who are at risk for developing NSAID-associated gastric ulcers. The company's common stock is traded on The Nasdaq Stock Market under the symbol "POZN". For detailed company information, including copies of this and other press releases, see POZEN's website: www.pozen.com.

Statements included in this press release that are not historical in nature are "forward-looking statements" within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. You should be aware that our actual results could differ materially from those contained in the forward-looking statements, which are based on management's current expectations and are subject to a number of risks and uncertainties, including, but not limited to, our failure to successfully commercialize our product candidates; costs and delays in the development and/or FDA approval of our product candidates, including as a result of the need to conduct additional studies, or the failure to obtain such approval of our product candidates, including as a result of changes in regulatory standards or the regulatory environment during the development period of any of our product candidates; uncertainties in clinical trial results or the timing of such trials, resulting in, among other things, an extension in the period over which we recognize deferred revenue or our failure to achieve milestones that would have provided us with revenue; our inability to maintain or enter into, and the risks resulting from our dependence upon, collaboration or contractual arrangements necessary for the development, manufacture, commercialization, marketing, sales and distribution of any products; competitive factors; our inability to protect our patents
'"/>




Page: 1 2 3

Related medicine technology :

1. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
2. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
3. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
4. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
5. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
8. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
9. Protox Announces Positive Clinical Data from Prostate Cancer Study
10. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
11. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: POZEN Announces Positive Outcome for Proof Concept Study
(Date:9/19/2014)... LYNBROOK, N.Y. , Sept. 19, 2014  BioSpecifics Technologies ... first in class collagenase-based products marketed as XIAFLEX ® ... announced today that BioSpecifics, President, Tom Wegman , will ... BioCentury NewsMakers in the Biotech Industry Conference. ... at 3:00 p.m. EDT at the Millennium Broadway Hotel in ...
(Date:9/19/2014)... , Sept. 19, 2014 Intarcia Therapeutics, ... clinical data for its lead candidate ITCA 650 (continuous ... with high baseline HbA1c levels at the 50 th ... Study of Diabetes (EASD). Data from the open-label, phase ... of blood sugar in patients with poorly controlled type ...
(Date:9/19/2014)... 19, 2014  PCI is pleased to announce ... is a leading provider of Clinical Trial Services ... Wales in the ... expands PCI,s presence in the UK/EU to support ... packaging, storage and distribution capacity, as well as ...
Breaking Medicine Technology:BioSpecifics Technologies Corp. to Present at the 21st Annual BioCentury NewsMakers in the Biotech Industry Conference 2Intarcia Announces Presentation of Phase 3 Data at EASD Showing ITCA 650 Markedly Reduces Blood Sugar In Patients With Poorly Controlled Type 2 Diabetes 2Intarcia Announces Presentation of Phase 3 Data at EASD Showing ITCA 650 Markedly Reduces Blood Sugar In Patients With Poorly Controlled Type 2 Diabetes 3Intarcia Announces Presentation of Phase 3 Data at EASD Showing ITCA 650 Markedly Reduces Blood Sugar In Patients With Poorly Controlled Type 2 Diabetes 4PCI Announces Acquisition Of Biotec 2PCI Announces Acquisition Of Biotec 3PCI Announces Acquisition Of Biotec 4PCI Announces Acquisition Of Biotec 5PCI Announces Acquisition Of Biotec 6
... NEW YORK, Jan. 10, 2012  ( http://www.myprgenie.com/  ) ... Americans 10 years ago and ask them where they found ... their current healthcare provider in their insurance plan directory or ... that is not the case.  Eighty percent of all U.S. ...
... uVera Diagnostics has introduced the CR3 Keyless Split Sample Cup ... cup provides several state-of-the-art features not available together in any ... to the drug testing industry," said Rick Nee, president of ... of use for both genders. The unique patented device is ...
Cached Medicine Technology:Castle Connolly Makes Finding the Best Healthcare from Top Doctors Even Easier 2uVera Diagnostics Offers New Drug Screening Product 2
(Date:9/19/2014)... (PRWEB) September 20, 2014 As summer vacations ... DMD in Queens, NY now reminds area patients about the ... 80% of our population affected by gum disease, there is ... , For over 20 years Dr. Krishnan has treated patients ... office location. “Most patients that come in due to common ...
(Date:9/19/2014)... Majidi, M.D., a second-year resident in the Department ... of Medicine and Health Sciences, received at $154K ... the presence of diffuse brain swelling and injury ... to epidemiological studies, intracerebral hemorrhage accounts for less ... the least treatable form of stroke, with the ...
(Date:9/19/2014)... BCC Research reveals in its new ... , the global market for human antifungal therapeutics is ... with a five-year compound annual growth rate (CAGR) of ... a steady 3.8% CAGR. , Given the current world ... with the incidence of increasing mortality and the severity ...
(Date:9/19/2014)... Dallas, Texas (PRWEB) September 19, 2014 ... blocking the physiologic actions of leukotriene D4 (LTD4). LTD4 ... released from a variety of cells, including mast cells ... CysLT receptors. Several studies have determined that there are ... of asthmatics compared with non-asthmatic individuals. The production of ...
(Date:9/19/2014)... San Jose, California (PRWEB) September 19, 2014 ... agents, an integral part of the medical imaging market, ... organs. Effervescent technology developments over the past three decades ... medical diagnostics. From barium and iodine based agents used ... as gold nanoparticles and radiopharmaceuticals, imaging agents have witnessed ...
Breaking Medicine News(10 mins):Health News:New York Periodontist Dr. Prabha Krishnan Now Raises Awareness about the Dangers of Untreated Decay, Gingivitis and Gum Disease During Self-Awareness Month 2Health News:New York Periodontist Dr. Prabha Krishnan Now Raises Awareness about the Dangers of Untreated Decay, Gingivitis and Gum Disease During Self-Awareness Month 3Health News:GW researcher receives grant to study brain swelling following bleeding in the brain 2Health News:Global Market for Human Antifungal Therapeutics to Reach Nearly $13.9 Billion in 2018; Over-The-Counter (OTC) Segment Growing At 3.8% CAGR 2Health News:Global Market for Human Antifungal Therapeutics to Reach Nearly $13.9 Billion in 2018; Over-The-Counter (OTC) Segment Growing At 3.8% CAGR 3Health News:Singulair Asthma Market to 2023 – Etiology, Pathophysiology, Diagnosis & Treatment Overview in New Report Available at LifeScienceIndustryResearch.com 2Health News:Singulair Asthma Market to 2023 – Etiology, Pathophysiology, Diagnosis & Treatment Overview in New Report Available at LifeScienceIndustryResearch.com 3Health News:Singulair Asthma Market to 2023 – Etiology, Pathophysiology, Diagnosis & Treatment Overview in New Report Available at LifeScienceIndustryResearch.com 4Health News:New Clinical Applications and Advanced Imaging Capabilities Drive Growth in the Imaging Agents Market, According to New Report by Global Industry Analysts, Inc. 2Health News:New Clinical Applications and Advanced Imaging Capabilities Drive Growth in the Imaging Agents Market, According to New Report by Global Industry Analysts, Inc. 3Health News:New Clinical Applications and Advanced Imaging Capabilities Drive Growth in the Imaging Agents Market, According to New Report by Global Industry Analysts, Inc. 4
... Aug. 13 As reported in publications and news,outlets ... "buck" teeth was replaced at the summer games opening ... the decision spawned,disbelief around the globe, sadly, the phenomenon ... of their teeth is nothing new., In a ...
... donations for breast cancer,research/programs, DETROIT, Aug. 13 ... part to end cancer, as well as honor the ... goal of walking 18,marathons in 18 days -- The ... cancer research and programs at the Barbara Ann Karmanos ...
... 3 new reports raise question of how long a heart ... 13 (HealthDay News) -- Three new reports challenge current guidelines ... taking a heart from an infant organ donor. , There,s ... no question that there aren,t enough donor organs to save ...
... Weiner Says Calls for,Privatization and ,Reform, are Granny-on-Your-Own, ... WASHINGTON, Aug. 13 On Social Security,s,73rd Anniversary ... of Staff,Robert Weiner is saying, "Calls to ,reform, ... Street,giveaway which would turn Social Security from a ...
... Held Thursday, August 14, 2008 at 9:00 a.m. Eastern ... ... Alseres,Pharmaceuticals, Inc. (Nasdaq: ALSE ) today reports operational and,financial results ... year 2008., (Logo: http://www.newscom.com/cgi-bin/prnh/20080813/NEW056LOGO ), "Alseres made solid ...
... -- Lotus,Pharmaceuticals, Inc. (OTC Bulletin Board: LTUS) ("Lotus" ... Republic of China,("PRC"), today announced that it will ... on Monday, August 18, 2008 to discuss results ... Dr. Zhongyi Liu, Chairman and Chief Executive Officer ...
Cached Medicine News:Health News:Summer Games 'Swap' Raises Questions About Image, Oral Health 2Health News:More Than 400-mile Victory Walk to Conclude Aug. 14, at Campus Martius 2Health News:More Than 400-mile Victory Walk to Conclude Aug. 14, at Campus Martius 3Health News:Infant Heart Transplant Controversy Continues 2Health News:Infant Heart Transplant Controversy Continues 3Health News:Infant Heart Transplant Controversy Continues 4Health News:Social Security's 73rd Anniversary 2Health News:Alseres Pharmaceuticals, Inc. Reports Second Quarter 2008 Operational and Financial Results 2Health News:Alseres Pharmaceuticals, Inc. Reports Second Quarter 2008 Operational and Financial Results 3Health News:Alseres Pharmaceuticals, Inc. Reports Second Quarter 2008 Operational and Financial Results 4Health News:Alseres Pharmaceuticals, Inc. Reports Second Quarter 2008 Operational and Financial Results 5Health News:Alseres Pharmaceuticals, Inc. Reports Second Quarter 2008 Operational and Financial Results 6Health News:Lotus Pharmaceuticals Announces Conference Call to Discuss Second Quarter 2008 Results 2
... Volks revolutionary MiniQuad, the DynaView 156 is ... of the retina extending to the ora ... patients. Featuring a minified housing and reduced ... revolutionizes retinopathy of prematurity surgery and is ...
... If you prefer a standard ... the Volk Iridectomy Lens. Its ... view you're used to but ... Volk's exclusive Double Aspheric design ...
... re-designed Super Macula® 2.2 offers extremely high ... fovea, while achieving an exceptionally wide 78° ... excellent choice for critical evaluation of the ... for detailed views of the macula and ...
... The Volk TransEquator is designed for ... diagnosis. Its unique optical design presents a ... an impressive wide-field view of the entire ... superior optics of this lens allows dynamic ...
Medicine Products: